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INTRODUCTION 
 Advancements in genetics research are rapidly transforming the fields of personalized 
medicine and population research. These developments will introduce a wide range of difficult 
bioethical issues and raise many yet unaddressed legal concerns. On September 5, 2012, Nature, 
Cell, Science, Genome Research, and other scientific journals released a coordinated publication 
of thirty articles detailing the groundbreaking findings of The Encyclopedia of DNA Elements 
(ENCODE) consortium.
1
 The ENCODE consortium represents new research that for the first 
time confirms that over eighty percent of our DNA which was once thought of as “junk” with no 
function actually plays a “critical role in controlling how cells, tissue, and organs behave.”2 
These portions of the genome, once disregarded as non-protein-coding DNA (ncDNA) are now 
being described as genetic “switches” that may lead to many discoveries about disease.3  
Imagine a patient walking into his physician’s office, handing the physician a memory 
stick and saying: “Here, look at all 3.2 billion base pairs of my DNA and tell me exactly what is 
wrong with my cancer and how you are going to treat it.” According to Dr. George Sledge Jr., a 
past president of the American Society of Clinical Oncology, this scenario could become a 
reality in as few as two to three years.
4
 Advancements in the field of genetic testing will change 
clinical practices and patient expectations, which will shift boundaries of medical malpractice 
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law, expand the meaning of informed consent, and present new challenges in bioethics and 
privacy.  
 Although there is much to be gained from learning more about individual genomes, 
genetic information can reveal highly sensitive personal information such as medical history, 
familial relationships, predisposition for disease, and possibly even behavioral tendencies.
5
 The 
government has already recognized the potential gains from genetic testing, as well as the 
concerns that individuals might have about the confidentiality of their genetic information.
6
 The 
Genetic Information Nondiscrimination Act was enacted to address these concerns and promote 
genetic testing.
7
 It is likely that GINA and other protective privacy measures will encourage 
more individuals to undergo genetic testing.  
 As more about the human genome is revealed and more patients choose to undergo 
genetic testing, it is increasingly important to develop professional guidelines and 
recommendations that take into account new genetic discoveries and testing techniques. In order 
to provide an argument in support of the further development of professional guidelines, this 
paper will consist of four sections. Section I will discuss the background of genetic testing, the 
Human Genome Project and the ENCODE Consortium. Section II will explore the legal issues 
surrounding genetic testing and discuss the implications that increased genetic testing will have 
on the doctrines of medical malpractice and informed consent. This section will also discuss how 
the law will be challenged by rapidly developing advancements such as the ability to detect 
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genetic “switches.” Section III will examine the unique legal and bioethical concerns that arise 
from the interplay between patient privacy and the duty to warn third parties of genetic diseases. 
Finally, Section IV will conclude that in order to promote the advancement of personalized 
medicine, it will be important to increase genetics education and establish professional 
guidelines that recognize advancements made in whole genome sequencing while preserving 
patient confidentiality.  
I. ENCODE: THE NEW FRONTIER OF GENETIC TESTING 
 Technological innovation has made genetic testing more accessible and an increasing 
number of individuals now have the opportunity to access and interpret their own genetic 
information.
8
 The price of sequencing an entire human genome is dropping rapidly and it may 
soon cost a consumer only $1,000 for an entire genetic blueprint.
9
 This genetic blueprint can 
reveal predispositions to cancer, diabetes, and even psychiatric conditions.
10
 The cost of 
sequencing the entire genome, consisting of more than 20,000 genes and 6 billion DNA building 
blocks, will soon be less than that to perform individual tests for cancer or metabolic disease.
11
  
Whole genome sequencing has already made promising developments in the field of 
targeted gene therapy.
12
 In 2009, the Memorial Sloan Kettering Cancer Center conducted a phase 
II trial of the kidney cancer drug Everolimus on patients with bladder cancer.
13
 Although the trial 
was unsuccessful overall, one patient (Patient X) responded remarkably well to the drug and 
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went into complete remission.
14
 The researchers then used array-based tools to perform a 
targeted search of the Patient X’s tumor DNA for mutations and variations.15 When that did not 
produce significant results, they sequenced the tumor’s entire genome to detect potential 
biomarkers.
16
 This whole genome sequencing revealed that there were indeed two mutations 
unique to Patient X.
17
 Upon referencing previous studies, scientists discovered that one of these 
mutations had been shown to sensitize patients to the same protein that is targeted by Everolimus, 
likely deducing the source of Patient X’s positive response.18 Scientists believe that experiments 
in this vein can continue to identify previously undetected subtypes of disease that can then be 
targeted and treated through personalized therapies.
19
  
Whole genome sequencing will likely increasingly be used as a discovery platform.
20
 
Namely, the federal government spent $288 million to support development of the Encyclopedia 
of DNA Elements (ENCODE), an international research collaboration that follows up on and 
supplements the Human Genome Project (HGP).
21
 The goal of the HGP, an international, 
collaborative research program jointly managed by the U.S. Department of Energy and the 
National Institutes of Health, was to map and sequence the genes of the human body.
22
 In 2003, 
the HGP was successfully completed.
23
 ENCODE now aims to provide a deeper understanding 
of the “functional” elements of the genome and serve as a catalog of these segments.24 
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 One of ENCODE’s most ground-breaking discoveries is that certain non-protein coding 
regions serve much larger functions than previously thought.
25
  So far, four million switches, 
also called transcription factors or “regulatory genes,” have been discovered.26 Study results 
found that regulatory genes are responsible for common diseases such as Crohn’s disease and 
about 17 major different types of cancer. 
27
 Gaining understanding of these networks of genetic 
switches may prove to provide new targets for drug therapy and greatly expand personalized 
medicine.
28
 Namely, genome-based research will eventually allow scientists to develop highly 
effective diagnostic tests to better understand the health needs of people based on their unique 
genetic make-ups, and to design personalized treatments for diseases.
29
  
Laboratories and clinicians will benefit from collaborating to understand the relationships 
between sequence variations and health conditions within the context of ENCODE’s findings. 
Clinical decisionmakers will be also need to take these findings into account in order to avoid 
inappropriate recommendations that may cause patient harm.
30
 As data on current practices on 
genetics reporting and its impact on health outcomes continues to accumulate, it will be 
important to survey these practices and how they link to patient outcomes. These new 
discoveries will reshape the boundaries of medicine and should be taken into account when 
addressing legal and bioethical quandaries that will inevitably arise as genetic testing becomes 
more prevalent. 
II. THE CHANGING LANDSCAPE OF LIABILITY 
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 The possibility of linking DNA variations with health conditions will result in 
unprecedented ways to predict and treat diseases.
31
  In a pilot study Mike Snyder, the head of the 
Center for Genomics and Personalized Medicine and Stanford University, decided to sequence 
his own genome in order to demonstrate the capabilities of personal genomics.
32
 Snyder 
explained that he wanted to sequence his DNA to see if it would predict conditions that he might 
be at risk for, particularly those that were not evident from his family history.
33
 The sequencing 
revealed that the seemingly healthy Snyder was at high risk for type 2 diabetes.
34
 Snyder stated 
that he believed that the early detection would allow him to manage the risk through diet and 
increased exercise, thereby mitigating an otherwise debilitating disease.
35
 
Although advancements in whole genome research will play a role in making medicine 
more preventative, personalized and effective, there are significant gaps in the U.S. system of 
genetic testing oversight that can lead to harms.
36
 Further, customs in the genomics industry are 
not yet fully developed.
37
 As genetic testing continues to grow exponentially, the number of 
qualified clinical geneticists and genetic counselors is unlikely to meet the demand, and an 
increasing amount of general physicians may be expected to offer, interpret and convey genetic 
tests results.
38
 Thus, increased validation and acceptance of genetic testing in clinical practice 
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could result in a challenging time for physicians.
39
 Physicians will be at the forefront of genetics 
medicine and may be faced with changing forms of liability for medical malpractice, lack of 
informed consent, and the legal duty to warn.  
1. Medical Malpractice: Standard of Care 
 As physicians incorporate genetic services into their practice, the framework for 
analyzing medical malpractice cases will change. Medical malpractice claims are based on 
negligence
40
 and must include a duty owed by the physician to his patient, a breach of that duty, 
causation, and damages.
41
 The physician-patient duty is unique in that it is upheld if the 
physician meets the required standard of care.
42
 Generally, the standard of care is measured by 
the level of care demonstrated by other physicians in the same field in terms of skill, knowledge 
and care.
43
 
 Genetics knowledge, skills, and abilities vary greatly across the discipline, making it 
difficult to make standard of care determinations. In a survey of six allied healthcare training 
programs, 78 percent of graduates reported that they received marginal to no instruction on 
genetics knowledge and skills.
44
 However, even though they had minimal levels of genetics 
education, these professionals were still responsible for providing clinical services relevant to 
genetics, such as taking family genetic histories and counseling patients on the genetic basis for 
the disorders.
45
 As the personal genomics industry grows, it will be important for primary care 
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providers to equip themselves with the necessary knowledge and skills to assess patients’ 
situations. The wide range of genetics care providers, ranging from geneticists who have medical 
degrees to laboratory technicians, implies that some types of providers may be more qualified 
than others depending on the nature of the test and the complexity of the condition at issue.
46
 
Currently, the American Medical Association (AMA) predicts that only ten percent of 
physicians possess the requisite knowledge to use genetic testing.
47
 Due to the low percentage of 
general physicians who genetic testing services, it may be difficult to establish a standard of care 
that would give rise to liability for failure to administer genetic testing services.
48
 However, as 
more genetic tests for common chronic disorders become incorporated into primary practice, 
even health care professionals who do not have specialized training in genetics may be held to 
the same standard of care as clinical geneticists. This may impose general practitioners with a 
heightened standard of care and resulting malpractice cases that they are not prepared to prevent.  
This issue is compounded by the fact that patients may be more confident in their primary 
physicians’ ability to convey genetic services than statistics should currently suggest.49 The 
AMA reported in a survey that over 60 percent of respondents would choose their primary care 
doctor as their first consultant on genetic disorders.
50
 In addition, about 80 percent reported 
feeling “very confident” or “somewhat confident” that their primary care provider could advise 
them or their family members about risk for developing inherited cancer, counsel them about 
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available genetic tests, and interpret results from the test.
51
 However, a separate study conducted 
by the National Cancer Institute concluded that only 40 percent of primary care physicians and 
57 percent of tertiary care physicians felt that they were qualified to recommend genetic testing 
for cancer susceptibility to their patients.
52
 
Studies have shown that the level of genetics knowledge of the primary care provider 
greatly determines willingness to offer genetic testing and services.
53
 Attitudes and acceptance of 
testing are also dependent on complex balancing tests of the benefits, risks, and costs of genetic 
testing.
54
 Notably, providers will be faced with the challenge of constantly maintaining 
knowledge of what tests are currently available, and how accurate and valid the tests are.
55
 The 
burden of attaining rapidly changing knowledge about genetics, including new findings that 
come from ENCODE, may prove to be a deterrent for providers who do not wish to incur 
liability for care related to genetic services.
56
  
Further, even if a physician purports not to offer genetics services, plaintiffs may still 
succeed in bringing a case under the current standard of care. According to the Restatement 
(Second) of Torts, “[i]n determining whether conduct is negligent, the customs of the community, 
or of others under like circumstances, are factors to be taken into account, but are not controlling 
where a reasonable man [or woman] would follow them.”57 For example, if there is sufficient 
knowledge in the medical community that a certain set of gene mutations cause a particular 
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disease to develop, and the physician does not follow up with a patient whose medical records 
show these gene mutations which in turn lead to that patient’s injuries, the physician could face 
liability under this standard.
58
 The physician may argue that due to his limited background in 
genetics related care, medical custom would not dictate him to follow up with his patient 
regarding the predicted disease.
59
  
However, if a reasonable person, given the prominence of the predictive test, would have 
conducted follow up care, medical custom may not prescribe the outcome.
60
 This reasonable 
person objective standard has been applied by at least one court in a medical malpractice 
setting.
61
 In Helling v. Carey, the court stated that although an early glaucoma detection 
technique using air puffs tests was not in routine use by ophthalmologists, the court could impose 
liability for breaching the standard of care.
62
 The court stated that “irrespective of its disregard 
by the standards of the ophthalmology profession, it is the duty of the courts to say what is 
required to protect patients.”63 Under this same reasoning, the lifesaving potential of genetic 
testing and follow up care could lead courts to impose liability for physicians who fail to utilize 
available testing and care.  
 Physicians who do choose to offer genetic testing services will be exposed to even more 
forms of liability. For example, they could be held liable for an incorrect interpretation of test 
results and for recommending a suitable course of treatment or drug therapy. Further, physicians 
will have to consider the fact that simply revealing genetic information to patients could have 
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unexpected effects on the patients’ psyche.64 To prevent these situations, it will be crucial for 
physicians to establish obtain informed consent with patients before engaging in genetics 
services.  
2. Lack of Informed Consent as Liability 
 The theory of informed consent raises significant areas of liability for physicians. The 
need for informed consent is based in the principles of autonomy and self-determination and 
recognizes the patient’s desire to decide which tests and procedures to undergo.65 In order to 
establish informed consent liability, an injured patient must show that his physician failed to 
disclose all information pertinent to the test or procedure, including benefits, risks, and 
alternatives.
66
 The patient must also establish by a preponderance of evidence that if the patient 
had received all of the pertinent information, he would have chosen an alternative means of 
treatment.
67
 As applied to genetic testing, the injured patient might allege that, if given all the 
relevant information about undergoing a certain treatment plan, the patient would have asked for 
a genetic test to determine whether he would be negatively impacted by the treatment, and would 
have either avoided the treatment altogether or undertaken a alternative means of treatment.
68
  
 Similar to other medical malpractice claims, claims for lack of informed consent may be 
evaluated under the “reasonable practitioner” standard, which states that the plaintiff must 
establish what a reasonable physician would disclose to his patient, prove that his own physician 
failed to disclose than information, and then show that he was harmed by this lack of 
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disclosure.
69
 This standard, which has been relatively easy to meet due to the limited practice of 
genetic testing, may shift as genetic testing becomes more widespread.
70
 Further, some states 
hold physicians to an informed consent standard according to what a “reasonable patient” would 
need to know to make an informed decision.
71
 This patient-centered approach dictates that “the 
test for determining whether a particular peril must be divulged is its materiality to the patient's 
decision,” and that “all risks potentially affecting the decision must be unmasked.”72 Under this 
standard, patients who bring a cause of action for a physician’s failure to provide a genetic test 
would be required to show that a test was commercially available that would provide results that 
would dictate the patient’s course of action.73 However, if there was no test commercially 
available, then the information would not be considered materially relevant.
74
 Advancements in 
genetic testing techniques such as the ENCODE findings will increase the number, power, and 
accuracy of genetic tests, necessitating clear informed consent and communication between 
physicians and patients.
75
  
As findings from ENCODE and similar whole genome sequencing projects begin to 
disseminate throughout the medical community, physicians may increasingly be held liable for 
failure to provide genetic tests or failure to properly interpret those tests.
76
 In order to avoid 
liability, doctors may find it necessary to learn about these techniques and incorporate them in to 
their practice.
77
 Finally, physicians who do engage in genetic testing services will be faced with a 
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challenging legal and bioethical issue that pushes the boundaries of confidentiality and the 
physician-patient relationship: the duty to warn.  
 
III. THE DUTY TO WARN: INCREASING TENSION BETWEEN PATIENT CONFIDENTIALITY AND 
AVERTING HARM  
 
1. Legal Duty to Warn 
Genetic testing presents the unique problem of not only identifying the risk for disease 
for patients but also for family members who may not be receiving care from the physician 
providing the test.
78
 Most medical professional organizations take the policy position that 
physicians should actively encourage patients with inherited diseases to inform their at-risk 
family members.
79
 Certain hereditary diseases, such as breast cancer, have mutations that can be 
easily detected. Predictive tests, or susceptibility tests, include those for breast and ovarian 
cancer, colon cancer, and Alzheimer’s disease.80 In the case of breast cancer, mutations in 
BRCA1 and BRCA2 are highly associated with increased risk for both breast and ovarian 
cancer.
81
 Patients who test positive for mutations may elect for cancer prophylaxis or even take 
preventative measures such as mastectomies.
82
 However, patients who choose to take preventive 
measures for themselves may not want to reveal this sensitive information to family members.
83
  
Depending on the jurisdiction, the hereditary nature of genetic traits creates a unique 
situation for physicians who offer genetic testing to their patients but do not share test results 
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with the patients’ close relatives. For instance, in Florida84 and New Jersey,85 physicians have the 
duty to inform patients that they should warn close relatives if genetic testing reveals harmful 
genotypes.
86
 New Jersey courts have gone even further to say that warning the patient may not 
be enough, indicating that physicians may be required to give patients’ relatives direct warnings 
with whom they may have no physician-patient relationship.
87
 
 The physicians’ legal duty to warn was established in Tarasoff v. Regents of the 
University of California.
88
 In Tarasoff, a woman was murdered by a man who was obsessed with 
her after he had shared his intention to kill her with his psychotherapist.
89
 The court held that a 
physician has a duty to warn if 1) he has a special relationship with either the person who may 
cause harm or the potential victim, 2) the person at risk is identifiable, and 3) the harm is 
foreseeable and serious.
90
 The Tarasoff duty to warn identifiable individuals at risk of harm is 
significant for physicians in the context of genetic testing because genetic test results may 
identify potential risk of harm for patients’ relatives.91  Particularly, case law has suggested that 
physicians may have a duty to disclose genetic information to families of patients when related 
individuals may need it to make informed reproductive choices
92
 or when they are genetically 
susceptible to potentially harmful genetic traits demonstrated in the physician’s patient.93  
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For example, In Pate v. Threkel,
94
 Heidi Pate, the adult daughter of a woman who had 
thyroid carcinoma, a genetically inheritable disease, sued her mother’s physician for medical 
malpractice after she developed the same disease three years after her mother’s treatment was 
completed.
95
 Her complaint stated that her mother’s physician knew or should have known that 
the disease was hereditary and that the physician had a duty to warn her mother that her that her 
children should be tested for the disease.
96
 Further, she alleged that if her mother had been 
warned, she would have had her children tested, and that if Pate had been tested at that time, she 
would have taken preventive action and could have cured her condition.
97 
 
The Florida court ruled that the physician did have a duty to warn Pate’s mother due to 
the genetically transferable nature of her disease,
98
  and that this duty should run to the “intended 
beneficiary of the prevailing standard of care.” 99 As the patient’s child, the court said, Pate was 
an intended beneficiary of her mother’s care, and the lack of a direct physician-patient 
relationship did not “foreclose liability if a duty of care [was] otherwise established.”100 Thus, in 
cases in which the prevailing standard of care creates a duty that is intended to benefit 
identifiable third parties, then the physician's duty extends to those third parties.
101
 However, the 
court was careful to note that the physician was not required to personally warn the patient's 
children.
102
 They duty would be satisfied “in any circumstances in which the physician has a 
duty to warn of a genetically transferable disease,” by warning the patient.”103 
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In a similar New Jersey case, Safer v. Estate of Pack, a patient diagnosed with a 
hereditary form of colon cancer brought a malpractice claim against the estate of the physician 
who had treated her father thirty-four years earlier, alleging that the doctor had breached his duty 
to warn her that she was at risk of developing the hereditary disease.
104
 Although there was no 
direct physician-patient relationship, the court stated that a doctor had a duty to warn those 
“known to be at risk of avoidable harm from a genetically transmissible condition,”105and 
postured that there was no “essential difference” between protecting third parties from 
contagious disease or physical harm and protecting them from potential genetic disease.
106
 In 
certain situations, “[t]he individual or group at risk is easily identified, and substantial future 
harm may be averted or minimized by a timely and effective warning.”107 Notably, unlike 
the Pate court, the Safer court did not assert that a physician satisfies his duty to warn 
of avoidable risks by informing only the patient of the disease’s hereditary nature.108 Rather, the 
court stated that duty to warn can be discharged, especially with respect to at-risk children, if 
reasonable steps are taken to assure those most likely to be affected are given the proper 
information.
109
 Finally, while the court recognized that there was a potential conflict between its 
stated duty to warn and physician-patient confidentiality, it elected not to resolve that issue.
110
  
2. Ethical Duty to Warn- The Importance of Maintaining Patient Confidentiality 
 The tension between physicians’ duty to warn third parties of genetic disease through 
familial risk and the duty to respect their patients’ confidentiality is a difficult conflict with 
ethical implications. Genetic test results may impact individuals and their families with 
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implications for obtaining insurance and employment and affect decisions pertaining to 
childbearing, diet, and physical activities.
111
 Specifically, “genetic predestination” is a theory 
that may significantly alter the lives of those who learn the results of their genetic tests.
112
 As 
genetic testing becomes more common and whole genome sequencing is able to reveal more 
accurate results about an individual’s health, physicians need maintain their primary obligations 
of promoting the best interests of their patients.
113
 However, physicians should also make best 
efforts to cooperate with the patient in informing at-risk family members or obtain consent to 
inform them.
114
  
According to the National Human Genome Research Institute (NHGRI), due to the 
complexity of the decision about whether to be tested for genetic disease, it is recommended that 
those considering undergoing testing first consult with genetic counselors who are trained to 
“help individuals and families weigh the scientific, emotional, and ethical considerations” that 
may impact their decision.
115
 In fact, as the amount of genetic information resulting from the 
HGP and ENCODE increases, physicians may soon have the professional responsibility to 
ensure that their patients receive genetic counseling in appropriate cases.
116
 Physicians who offer 
genetics services may be expected to assess the risk of a genetic disorder by researching and 
evaluating family history and medical records, interpreting the results of genetic tests and 
medical data, and explaining possible treatments, preventive measures, and reproductive 
options.
117
 In addition, they may need to weigh the medical, social, and ethical decisions 
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surrounding genetic testing, provide support and information relevant to the decision, counsel or 
refer individuals and their families to support services, and serve as patient advocates.
118
 As 
physicians who perform genetic tests are faced with rising standards of care, they must carefully 
consider their ethical obligations to their patients, patients’ families, and society as a whole. 
 Significant bioethical concerns, such as the duty to preserve confidentiality of medical 
information, will emerge as genetic testing becomes more predictive. This duty, which is rooted 
in respect for the patient’s autonomy, dictates that physicians must maintain the confidentiality 
of their patients’ genetic information and abide by best-practices to avoid potentially 
unauthorized or inappropriate disclosure of patients’ genetic data.119 Patients may not want to 
share results with family members for fear of backlash or concern, and this should be taken into 
account even when potential of risk to family members is high.  
The duty to warn, which is based the principles of beneficence and nonmaleficence, 
supports the disclosure of relevant genetic information to family members who might be 
affected.
120
  The principle of justice recommends that family members have the right to the same 
access to testing and options to reduce risk as patients who receive tests.
121
 Disclosure of genetic 
test results may greatly benefit family members by giving them necessary access to surveillance 
and preventative therapies that could reduce the risk of developing the disease.
122
 Nondisclosure 
may actually harm at-risk relatives who might develop the familial condition without their 
knowledge.
123
 In addition, delayed diagnosis could limit treatment options and curability.  
Professional associations, such as the AMA, have recognized that while physicians must protect 
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the confidentiality of patient disclosures and information, “countervailing societal interests” may 
justify the breach of confidentiality.
124
 Disclosure may be justified particularly when the at-risk 
relative is identifiable, the genetic disorder is highly likely to be present, the disorder is treatable 
or preventable, and medically accepted standards indicate that early monitoring will reduce the 
genetic risk.
125
 Under all circumstances, the harm that would result from failure to disclose 
should outweigh the harm that may result from the disclosure.
126
 
The reasons for this ethical position are significant. First, the physicians’ duty to protect 
patient confidentiality, especially with respect to highly sensitive health conditions, is stronger 
than the duty to warn family members with whom no physician-patient relationship has been 
established.
127
 Although third parties may stand to benefit from being informed of their relatives’ 
genetic test results, the development of whole genome sequencing and increased genetic testing 
supports an emphasis on respect for patient autonomy. Namely, disclosure to third parties 
without the patient’s consent should only be recommended in exceptional situations where it is 
the last resort.
128
 As genetic testing becomes more common among the patient population, it is 
less likely that relatives will be harmed by the failure of their relatives’ physician to warn them 
of possible risk, making it less crucial for that physician to extend the duty to warn.  
Ideally, individuals should be able to have complete control their genetic information and 
its dissemination. To this end, physicians should strive to work with patients to obtain informed 
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consent and to cooperate in the responsible disclosure of test results to family members. Thus, it 
will be crucial to thoroughly counsel patients about the possible consequences of genetic testing, 
its limitations, implications for family members, and the right to protect the confidentiality of the 
information prior to undergoing genetic testing. The patient’s response to pre-test counseling and 
willingness to include family members in the testing progress should alert health care providers 
to potential communication problems within the patient’s family.    
On the other hand, decisions to disclose to at-risk family members must also consider 
respect for the autonomy of those family members and the “right not to know” about a relative’s 
genetic information.
129
  There are a number of potentially negative implications from sharing 
genetic test results with at-risk relatives. In addition to possible discrimination, the disclosure 
that one is genetically predisposed to or a carrier for a disease may cause devastating 
psychological and emotional damage.
130
 This may be particularly true for condition such as 
Huntington’s disease, when there is no cure for the disease and its onset is a virtual certainty.131 
Testing may also cause familial division if some members protest the test itself because they do 
not want to open an investigation into the family’s genetic reality.132 For these reasons, health 
care providers should not inform at-risk relatives of a patient’s genetic test results without first 
determining whether the relative would like to learn the information.
133
 However, an exception 
may be made when the patient is a minor and the potentially at-risk relatives are the child’s 
biological parents, because the parents may need this information to make informed decisions 
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about their child’s medical care and it may help parents make informed reproductive 
decisions.
134
 
Finally, when considering the duty to warn, physicians must assess the accuracy of the 
genetic test in question and avoid using tests that have not been evaluated for safety and 
effectiveness. Even if the genetic test generally provides accurate results for single-gene 
disorders, it might have significantly weaker predictive power for multifactorial disorders.
135
 
Heart disease, diabetes, most cancers, and Alzheimer's disease are examples of multifactorial 
disorders whose mutations often do not guarantee the onset of disease because they result from 
the interaction of multiple genes and environmental factors.
136
 The discoveries from ENCODE, 
and further knowledge about genetic switches, will likely shed light on the development of 
multifactorial disorders and hopefully increase the accuracy of predictive tests. Increasing 
accuracy may be able to provide at-risk relatives with clinically relevant information and enable 
them to take meaningful action to avoid future harm.  
The increase in the amount of genetic information available has led to the call for, and 
adoption of, new legislation on both state and federal levels to protect the confidentiality of 
genetic information and prevent discrimination based on genetic information in employment and 
health insurance contexts.
137
 However, there is no legislation that specifically speaks to the duty 
of health care providers to disclose genetic information about their patients to the relatives of 
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those patients.
138
 There is a need to enact a consistent floor of privacy protections covering 
whole genome sequence data and to prohibit unauthorized whole genome sequencing without 
full informed consent.  In addition to preserving patient privacy and confidentiality, many other 
steps need to be taken in order to ensure that the medical field is able to progress by allowing 
genetic testing and whole genome sequencing to fully advance. Until legislatures establish clear 
guidelines regarding a physician’s duty to warn relatives of their possible genetic risk, physicians 
may benefit from increased education and the creation of policies and guidelines in a 
professional code of conduct that recognizes current advancements in genetics medicine.  
IV. RECOMMENDATIONS: INCREASED EDUCATION AND UNIFORM STANDARDS  
 Newly emerging genetic discoveries and testing techniques such as whole genome 
sequencing are likely to be accompanied by an onslaught of litigation previously unseen by 
physicians and courts. Presently, the majority of physicians is not adequately trained and 
educated about advancements in genetic research and may be unaware of legal consequences. 
Currently,  no state or federal laws exist to address whole genome sequence data 
comprehensively, while specific laws designed to protect genetic information in general typically 
address where the data is collected and by whom, but may or may not offer protection. 
139
In 
order to assist the medical community to adopt these valuable new resources, as well as to 
provide courts with a suggested standard of care, it will be important to incentivize increased 
genetics education and a set of uniform medical practice guidelines.  
1. Increased Education  
                                                          
138
 L.J. Deftos, Genomic Torts: The Law of the Future--The Duty of Physicians to Disclose the Presence 
of a Genetic Disease to the Relatives of Their Patients with the Disease, 32 U.S.F. L. REV. 105, 131 
(1997). 
139
 Presidential Commission for the Study of Bioethical Issues, Privacy and Progress in Whole Genome 
Sequencing (Oct. 1, 2012), http://bioethics.gov/cms/sites/default/files/PrivacyProgress508.pdf.  
23 
 
In order to adapt to the changing field of medicine and for patients to benefit from 
scientific advancements, physicians will need to become better educated and trained in the field 
of genetic testing. Currently, primary care physicians are not adequately prepared to assume 
responsibility for their patients' genetic services. For example, in a survey of 124 primary care 
physicians, twenty percent were unaware that a predisposition to breast cancer could be 
determined by a genetic test.
140
  Another survey about primary care physicians' knowledge about 
genetic testing for colon cancer found that the physicians' incorrect interpretation of the test 
results would have led them to provide their patients with inaccurate information in 31.6% of the 
cases.
141
 These studies demonstrate what may happen as genetic tests become available for 
public use before physicians are properly trained in when and how to use them. If physicians 
have the duty to disclose genetic information to their patients, they will either have to undertake 
the testing themselves or refer to experts who can.
142
 Thus, it is clear that physicians need to 
become more familiar with the capabilities of genetic testing to advise their patients or risks or to 
refer them for genetics services.  
In order to assure that physicians receive adequate education and training, it will be 
crucial for more genetics teaching to be included in medical schools, residency programs, and 
medical board exams. It may be beneficial for physicians to obtain certifications to require 
demonstration of sufficient knowledge in genetics prior to providing genetically based health 
care.  Hospitals and health management organizations should require competence in the field of 
genetics a prerequisite to allowing them to provide genetic counseling or testing. Particularly in 
the context of managed care systems, primary care physicians occupy roles as the “gatekeepers” 
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of their patients' medical care and may be increasingly called on to interpret genetic test results 
for their patients.
143
  Moreover, as science reveals more about the origins of multifactorial 
disorders, the number of individuals potentially at risk for the development of these disorders 
will increase, and initial genetic risk assessments may become an expected standard in primary 
care medicine.
144
 Thus, there must be increased efforts to promote health professional education 
and access to information about advancements in genetics medicine. Although transitioning into 
this new realm will be challenging, new methods of genetic testing through early detection, 
prevention, and treatment, will benefit doctors, patients, and the health care of the nation.  
2. Professional Guidelines 
As new advancements in genetics are made, medical and legal communities must 
recognize their responsibilities to inform themselves of current developments and to create 
appropriate standards so that patients receive quality care. This may be accomplished by the 
creation of a regularly updated set of professional guidelines that may be used to guide 
enforcement to maintain the integrity of genetic testing. These guidelines should survey the 
current state of how physicians are using genetic testing in clinical practice and provide 
anticipatory recommendations on how to incorporate new techniques.  
 Promulgated guidelines should include what specific genetic tests should be designated 
as the “standard of care” and under what circumstances.145 For instance, the American Society of 
Clinical Oncology has already promulgated guidelines recognizing that cancer specialists may 
not currently be fully informed of the range of issues that are involved in genetic testing for 
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cancer risk.
146
 Medical professionals, especially those who work in genetic specialties, need to 
publish similar established standards of care.
147
  The development of practice guidelines and 
protocols for testing will help physicians by providing a reference for the changing standard of 
care and serve as strategies for patient management and clinical decision making.  
In addition to helping physicians with decision making in patient care management, 
courts may benefit from having these practice guidelines in malpractice litigation as a reference 
to the current standard of care. The U.S. tort system may allow compliance or noncompliance 
with these guidelines to support malpractice claims or defenses. This will help promote 
efficiency and uniformity and reduce wasteful litigation that may deter physicians from 
incorporating genetic counseling and testing into their practices. These guidelines may also be 
used for patient education and could possibly lower the risk of physician liability by resolving 
ambiguity as to the governing standard. Genetic malpractice actions may force physicians either 
to overuse genetic diagnostic testing to defend against genetic malpractice suits or to avoid 
genetic services altogether by making blanket referrals.
148
 Without such policies and guidelines 
physicians may fear litigation and may not be able act responsibly, leaving courts with the 
burden of determining when a duty exists.  
While new medical practice guidelines may increase physician sophistication and 
improve the quality of American health care, their promulgation will likely be met with some 
resistance from the medical community. Established guidelines will also not guarantee consistent 
results from courts. Compliance with medical practice guidelines does not assure that a court will 
find that a physician is not liable for malpractice. Rather,“[o]nce admitted into evidence, a 
practice guideline does not constitute a predetermined standard of care that a court is obligated to 
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apply.”149 From there, the court may consider other evidence regarding what the standard should 
be, and it may stray from the practice guidelines if it finds that other evidence about the standard 
is more persuasive.
150
  Although medical practice guidelines may not definitely establish the 
standard of care, they will become a necessary resource for courts to work from and a valuable 
reference particularly if it is periodically updated to include significant new advancements.  
3. Incorporation of Electronic Health Records 
 Finally, providers may also adopt and improve genetic testing practices by incorporating 
a system of “interoperable, clinically useful genetic laboratory test data and analytical tools into 
electronic health records to support clinical decisionmaking for the health care provider and the 
patient.
151
 Electronic health records may support maximal benefits from genetic tests by tracking 
family history and provide an efficient means of delivering genetic test results. Although the 
Genetic Information Nondiscrimination Act (GINA) prohibits health insurers and employers to 
discriminate on the basis of genetic information, patients may still have privacy concerns about 
the incorporation of their genetic information in electronic health records. Thus, physicians 
should encourage their patients to undergo testing by fully explaining existing privacy 
protections and available remedies. 
       CONCLUSION 
Whole genome sequencing and findings from ENCODE will make genetic testing more 
accurate and powerfully predictive. Increasing availability and enforced privacy protections will 
likely encourage more patients to undergo genetic testing. The ability to target and prevent 
diseases through personalized medicine will prove to be an invaluable tool that will benefit 
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physicians, patients, and the health care of the nation. Physicians liability for medical 
malpractice provides justice for harmed patients and may promote the advancement and 
proliferation of genetic testing. On the other hand, physician fear of frivolous lawsuits and the 
burden of acquiring a vast and unfamiliar body of knowledge may discourage physicians from 
engaging in these valuable new practices. In order to facilitate the growth of genetic testing 
capabilities, courts should provide relief to a plaintiff only when the physician failed to utilize 
appropriate care and demonstrated negligence. 
In order to meet evolving standards of care, it is important for physicians who conduct 
genetic tests to obtain the necessary skills and training in pretest and posttest education.
152
 
Clinicians who meet these qualifications must thoroughly discuss with patients the degree to 
which particular genetic risk factors correlate with the chance of developing the disease.
153
 
Further, physicians should clearly present the risks and benefits of available testing and inform 
patients of available genetic tests, including whole genome sequencing.
154
 If physicians are 
unsure or unqualified of the services they are offering, they should be responsible for referring 
their patients for further discussion.
155
 Clinicians should also be careful not to undertake testing 
until all the potential consequences of learning genetic information are thoroughly disclosed to 
the patient.
156
 In this context, it will be important to discuss potential effects of the patient’s well-
being and that of family members; and the possibility of adverse use by employers, insurers, or 
other institutions.
157
 Finally, if the patient’s genetic information reveals a condition that may not 
be treated or prevented, physicians should be given the right to refrain from revealing the 
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information to individuals other than the patient. Under all circumstances, it will be essential that 
physicians receive appropriate training and education in genetics, and that patients who undergo 
testing receive comprehensive genetic counseling.   
As physicians are positioned at the forefront of this new realm, they are the most 
qualified to establish the standard of care in genetic medicine. Thus, it will become imperative 
for physicians to establish professional guidelines that help courts to set the standard of care and 
serve as a reference in medical malpractices cases. Setting a baseline for the standard of care will 
foster the adoption of genetic medicine among physicians and allow courts to apply a uniform 
standard in medical malpractice cases. Once these standards of care have been established, the 
medical community must continue to establish and abide by these standards and remain abreast 
of current developments in genetics.  With both the medical and legal communities better 
prepared for the obstacles that will accompany newly emerging genetic technologies, the genetic 
revolution can continue to make unprecedented breakthroughs in personalized care.  
